Henry Schein (NASDAQ:HSIC) Reaches New 1-Year High on Strong Earnings

Shares of Henry Schein, Inc. (NASDAQ:HSIC) reached a new 52-week high on Tuesday following a better than expected earnings announcement. The company traded as high as $92.18 and last traded at $89.9540, with a volume of 188350 shares changing hands. The stock had previously closed at $86.51.

The company reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.03. The business had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. Henry Schein’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS.

Analyst Ratings Changes

A number of research analysts have recently issued reports on HSIC shares. Citigroup initiated coverage on Henry Schein in a research note on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective on the stock. BMO Capital Markets initiated coverage on Henry Schein in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target on the stock. Robert W. Baird set a $97.00 price target on Henry Schein in a report on Wednesday, May 6th. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Mizuho dropped their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $89.36.

Insider Transactions at Henry Schein

In related news, Director William K. Daniel purchased 10,000 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the purchase, the director owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.89% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. CYBER HORNET ETFs LLC bought a new position in Henry Schein during the 2nd quarter valued at $25,000. MUFG Securities EMEA plc bought a new stake in shares of Henry Schein in the 2nd quarter worth $27,000. Flagship Harbor Advisors LLC bought a new stake in shares of Henry Schein in the 4th quarter worth $30,000. Federated Hermes Inc. purchased a new stake in shares of Henry Schein in the fourth quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Henry Schein during the fourth quarter valued at about $37,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

The company has a market capitalization of $10.24 billion, a P/E ratio of 27.15, a price-to-earnings-growth ratio of 1.65 and a beta of 0.80. The business’s 50-day moving average is $82.44 and its two-hundred day moving average is $78.38. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.